GC Wealth Management RIA LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• GC Wealth Management RIA LLC increased its holdings in Thermo Fisher Scientific Inc. by 103.2% during the second quarter, bringing their total shares to 9,853, valued at approximately $3.995 million.
• Other institutional investors have also increased their positions in Thermo Fisher, with Brighton Jones LLC raising its stake by 28.9% in the fourth quarter, now owning 4,409 shares worth $2.293 million.
• Thermo Fisher Scientific reported $5.36 earnings per share for the last quarter, exceeding estimates and showing a 2.9% revenue increase year-over-year, along with a quarterly dividend of $0.43 per share.

GC Wealth Management RIA LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 103.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 9,853 shares of the medical research company's stock after acquiring an additional 5,005 shares during the period. GC Wealth Management RIA LLC's holdings in Thermo Fisher Scientific were worth $3,995,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the last quarter. Fifth Third Wealth Advisors LLC grew its stake in Thermo Fisher Scientific by 1.0% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 7,037 shares of the medical research company's stock valued at $3,502,000 after purchasing an additional 73 shares during the last quarter. Mirador Capital Partners LP grew its stake in Thermo Fisher Scientific by 3.3% during the 1st quarter. Mirador Capital Partners LP now owns 8,829 shares of the medical research company's stock valued at $4,393,000 after purchasing an additional 280 shares during the last quarter. Finally, Czech National Bank grew its stake in Thermo Fisher Scientific by 5.9% during the 1st quarter. Czech National Bank now owns 87,854 shares of the medical research company's stock valued at $43,716,000 after purchasing an additional 4,920 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $464.18 on Monday. The company has a market capitalization of $175.28 billion, a price-to-earnings ratio of 26.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The company's 50 day simple moving average is $476.70 and its 200-day simple moving average is $447.15.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at $56,937,881. This represents a 0.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last ninety days. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on TMO shares. Robert W. Baird upped their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a report on Friday, July 11th. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Finally, Evercore ISI lowered their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Sixteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.